Publication date: 03/11/2017
MDxHealth SA (Euronext: MDXH.BR) today announced that the company has entered into an agency service agreement for SelectMDx® with Swiss-based Unilabs, one of Europe's leading providers of clinical laboratory testing and medical diagnostic imaging services.
Under the terms of the agreement, Unilabs medical laboratory in Geneva Switzerland, will perform SelectMDx service testing for all its clinical labs in France, Portugal, Sweden, Norway, Denmark, Finland, UK, Italy and Switzerland. To offer this service through its network, the laboratory will purchase SelectMDx CE-marked IVD kits from MDxHealth.
"We are excited that Unilabs is going to offer SelectMDx service testing to their customers," said Dr. Jan Groen, CEO, MDxHealth. "The company's broad hospital network and commercial capabilities will significantly contribute to the successful market penetration of SelectMDx."
"We are delighted to offer SelectMDx to Unilabs customers," commented Dr Pierre-Alain Menoud, Head of Molecular Diagnostics at Unilabs, Switzerland. "This agreement with MDxHealth reinforces our commitment to providing urologists with a service test."
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby reducing healthcare costs.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
With over 199 laboratories and 44 imaging units and a broad catalogue of more than 2,500 diagnostic tests, Unilabs is one of Europe's leading providers of clinical laboratory testing and medical diagnostic imaging services. Headquartered in Geneva, Switzerland the Unilabs Group serves private and public healthcare providers, local governments, pharmaceutical companies and the general public. The company employs more than 6,900 people worldwide, successfully operates laboratory and medical diagnostic imaging facilities in 14 countries, and generates annual revenues of €800m in 2016. Its network of facilities provides its customers with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe. Please visit www.unilabs.com and follow us on Twitter.